GlassScriptPhysician profile
Belinda Ramirez
NPI 1548264146
$5,719.98
in general payments reported to CMS, 2019-2025
36 companies · $1,198 in 2025
The $1,198 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $235 · 2021: $486 · 2022: $982 · 2023: $1,286 · 2024: $1,233 · 2025: $1,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,716.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,848.94 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,043.94 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $288.83 | 2021-2025 | Tremfya, Stelara, Simponi |
| Lilly USA, LLC | $273.17 | 2024-2025 | Omvoh |
| Celgene Corporation | $189.87 | 2021-2024 | Zeposia |
| Redhill Biopharma INC. | $179.66 | 2023-2025 | Talicia, Movantik, Aemcolo |
| Takeda Pharmaceuticals U.S.A., INC. | $162.74 | 2019-2025 | Eohilia, Gattex, Entyvio |
| Ironwood Pharmaceuticals, INC | $157.77 | 2019-2024 | Linzess |
| Gilead Sciences, INC. | $136.86 | 2021-2022 | |
| Celltrion USA INC. | $124.90 | 2024-2025 | Vegzelma |
| Nestle Healthcare Nutrition INC. | $121.87 | 2022-2023 | |
| Pfizer INC. | $104.51 | 2019-2023 | |
| Madrigal Pharmaceuticals | $93.11 | 2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $84.17 | 2024-2025 | Zenpep, Vowst |
| Micro-Tech Endoscopy USA, INC. | $83.92 | 2020-2023 | Irrigation Tubing, Balloons |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $80.15 | 2019 | |
| Daiichi Sankyo INC. | $77.50 | 2023-2025 | Injectafer |
| Allergan, INC. | $73.89 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $70.85 | 2024 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $66.42 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $62.88 | 2023-2024 | Sucraid, Sucraid |
| Ardelyx, INC. | $54.06 | 2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $50.89 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $43.51 | 2022-2023 | Dificid |
| Braintree Laboratories, INC. | $35.58 | 2022-2024 | Suflave |
| Genzyme Corporation | $30.96 | 2023 | |
| Tersera Therapeutics LLC | $30.45 | 2022 | |
| Intercept Pharmaceuticals, INC. | $26.22 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $24.78 | 2023 | Dupixent |
| American Regent | $21.82 | 2025 | Injectafer |
| Fresenius Kabi USA, LLC | $16.85 | 2024 | Idacio |
| Exact Sciences Corporation | $16.52 | 2025 | The Cologuard Plus Collection Kit |
| Evoke Pharma, INC. | $16.11 | 2024 | |
| Olympus America INC. | $14.60 | 2021 | |
| Alfasigma USA, INC. | $11.68 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$30,140.85 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Belinda Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.